Literature DB >> 6171865

Treatment of human complement components C4 and C3 with amines or chaotropic ions. Evidence of a functional and structural change that provides uncleaved C4 and C3 with properties of their soluble activated froms, C4b and C3b.

I von Zabern, R Nolte, W Vogt.   

Abstract

Treatment of human components C4 and C3 with amines like hydrazine, ammonium hydroxide, and neutral ammonium salts or with chaotropic salts like KSCN and NaBr leads to complete loss of haemolytic activity. The pretreated components are, however, still active in formation of soluble C3 convertases. This activity pattern is reminiscent of the activities of C4 and C3 that have been activated by cleavage in the fluid phase. Indeed, the antigenic properties of pretreated C4 and C3 are similar to soluble C4b and C3b. The polypeptide chain structure of pretreated C4 and C3, is, however, identical to that of the untreated components when investigated by SDS gel electrophoresis. Pretreatment even reduces greatly the susceptibility of C4 to cleavage by C1s and of C3 to cleavage by classical and alternative pathway C3 convertases. Pretreated components have lost the ability to combine with EAC1 and EAC142, respectively; this fact explains their failure to exhibit haemolytic activity. In serum, pretreated C4 and C3 are cleaved in a manner similar to C4b and C3b. Amines and chaotropic ions cause the same functional and structural alterations, which are best explained by assumption of a conformational change. A similar transformation can also occur in C4 and C3 during preparation or storage.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6171865     DOI: 10.1111/j.1365-3083.1981.tb00152.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  18 in total

1.  Native conformations of human complement components C3 and C4 show different dependencies on thioester formation.

Authors:  L Isaac; D Aivazian; A Taniguchi-Sidle; R O Ebanks; C S Farah; M P Florido; M K Pangburn; D E Isenman
Journal:  Biochem J       Date:  1998-02-01       Impact factor: 3.857

2.  Limulus alpha 2-macroglobulin. First evidence in an invertebrate for a protein containing an internal thiol ester bond.

Authors:  P B Armstrong; J P Quigley
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

3.  The erythrocyte as instigator of inflammation. Generation of amidated C3 by erythrocyte adenosine deaminase.

Authors:  M K Hostetter; G M Johnson
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

4.  Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.

Authors:  T C Farries; P J Lachmann; R A Harrison
Journal:  Biochem J       Date:  1988-05-15       Impact factor: 3.857

5.  Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.

Authors:  T C Farries; P J Lachmann; R A Harrison
Journal:  Biochem J       Date:  1988-08-01       Impact factor: 3.857

Review 6.  The beta-Cys-gamma-Glu thiolester bond in human C3, C4, and alpha 2-macroglobulin.

Authors:  B F Tack
Journal:  Springer Semin Immunopathol       Date:  1983

Review 7.  The alternative pathway of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

8.  Ca2+-activated K+ efflux limits complement-mediated lysis of human erythrocytes.

Authors:  J A Halperin; C Brugnara; A Nicholson-Weller
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

9.  Hypokalemic nephropathy in the rat. Role of ammonia in chronic tubular injury.

Authors:  J P Tolins; M K Hostetter; T H Hostetter
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

10.  The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Biochem J       Date:  1986-05-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.